InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.036 0.002 (5.26%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$53 Notification regarding unquoted securities - IMM 13 Oct 2025 8:20PM $0.290 $0.036 fallen by 87.59%
$53 Successful Completion of FDA Project Optimus Requirements 13 Oct 2025 8:25AM $0.305 $0.036 fallen by 88.20%
$53 TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC 9 Oct 2025 8:35AM $0.290 $0.036 fallen by 87.59%
$53 Change of Director's Interest Notice - P Meyers 8 Oct 2025 10:03AM $0.290 $0.036 fallen by 87.59%
$53 Change of Director's Interest Notice - F Triebel 8 Oct 2025 10:01AM $0.290 $0.036 fallen by 87.59%
$53 Change of Director's Interest Notice - M Voigt 8 Oct 2025 10:00AM $0.290 $0.036 fallen by 87.59%
$53 Application for quotation of securities - IMM 1 Oct 2025 2:58PM $0.265 $0.036 fallen by 86.42%
$53 New investigator-initiated Phase II trial for Efti 22 Sep 2025 8:21AM $0.250 $0.036 fallen by 85.60%
$53 Becoming a substantial holder 12 Sep 2025 8:18AM $0.240 $0.036 fallen by 85%
$53 EFTISARC-NEO data accepted for oral presentation at CTOS 8 Sep 2025 9:04AM $0.235 $0.036 fallen by 84.68%
$53 Appendix 4E & 2025 Full Year Statutory Accounts 29 Aug 2025 9:30AM $0.245 $0.036 fallen by 85.31%
$53 FDA feedback received for head & neck cancer in CPS below 1 5 Aug 2025 9:26AM $0.260 $0.036 fallen by 86.15%
$53 Immutep Quarterly Activities Report and Appendix 4C 30 Jul 2025 8:25AM $0.270 $0.036 fallen by 86.67%
$53 TACTI-004 trial in progress poster to be presented at WCLC 29 Jul 2025 8:21AM $0.260 $0.036 fallen by 86.15%
$53 Abstracts Accepted for Presentation at ESMO Congress 2025 28 Jul 2025 9:27AM $0.260 $0.036 fallen by 86.15%
$53 Ceasing to be a substantial holder 25 Jul 2025 8:16AM $0.260 $0.036 fallen by 86.15%
$53 Ceasing to be a substantial holder 23 Jul 2025 5:40PM $0.240 $0.036 fallen by 85%
$53 Application for quotation of securities - IMM 18 Jul 2025 12:10PM $0.260 $0.036 fallen by 86.15%
$53 Application for quotation of securities - IMM 18 Jul 2025 12:09PM $0.265 $0.036 fallen by 86.42%
$53 Change in substantial holding 17 Jul 2025 8:19AM $0.250 $0.036 fallen by 85.60%
$53 Change in substantial holding 30 Jun 2025 4:39PM $0.240 $0.036 fallen by 85%
$53 Update on Phase I Study of IMP761 for Autoimmune Diseases 23 Jun 2025 8:33AM $0.235 $0.036 fallen by 84.68%
$53 Immutep Corporate Presentation 2 Jun 2025 8:21AM $0.285 $0.036 fallen by 87.37%
$53 Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial 26 May 2025 8:22AM $0.295 $0.036 fallen by 87.80%
$53 High Response Rates achieved in Lung Cancer in INSIGHT-003 15 May 2025 8:16AM $0.280 $0.036 fallen by 87.14%

76 - 100 of 780 results

Page 4 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.